BR9812305A - Análogos de rapamicina contendo tetrazol com meias vidas encurtadas - Google Patents

Análogos de rapamicina contendo tetrazol com meias vidas encurtadas

Info

Publication number
BR9812305A
BR9812305A BR9812305-0A BR9812305A BR9812305A BR 9812305 A BR9812305 A BR 9812305A BR 9812305 A BR9812305 A BR 9812305A BR 9812305 A BR9812305 A BR 9812305A
Authority
BR
Brazil
Prior art keywords
restenosis
analogs containing
autoimmune
shortened half
half lives
Prior art date
Application number
BR9812305-0A
Other languages
English (en)
Inventor
Karl W Mollison
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25470968&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9812305(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of BR9812305A publication Critical patent/BR9812305A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"ANáLOGOS DE RAPAMICINA CONTENDO TETRAZOL COM MEIAS VIDAS ENCURTADAS" Um composto tendo a fórmula (I) ou um seu sal ou pró-droga farmaceuticamente aceitável, é um agente imunomodulador e é útil no tratamento de restenose e doenças imunes e autoimunes. Também são mostradas composições de inibição de doença autoimune e imune, rejeição de tecido pós-transplante, restenose, crescimento de fungo, câncer e um processo de inibição de câncer, crescimento de fungos, restenose, rejeição de tecido pós-transplante, e doença imune e autoimune em um mamífero, com minimizados efeitos colaterais devido a meias-vidas encurtadas.
BR9812305-0A 1997-09-26 1998-09-24 Análogos de rapamicina contendo tetrazol com meias vidas encurtadas BR9812305A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93814497A 1997-09-26 1997-09-26
PCT/US1998/020111 WO1999015530A1 (en) 1997-09-26 1998-09-24 Tetrazole-containing rapamycin analogs with shortened half-lives

Publications (1)

Publication Number Publication Date
BR9812305A true BR9812305A (pt) 2000-09-05

Family

ID=25470968

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9812305-0A BR9812305A (pt) 1997-09-26 1998-09-24 Análogos de rapamicina contendo tetrazol com meias vidas encurtadas

Country Status (28)

Country Link
EP (1) EP1015459B9 (pt)
JP (1) JP3790424B2 (pt)
KR (3) KR100803639B1 (pt)
CN (1) CN1161360C (pt)
AR (1) AR015940A1 (pt)
AT (1) ATE297398T1 (pt)
AU (1) AU745576B2 (pt)
BG (1) BG64955B1 (pt)
BR (1) BR9812305A (pt)
CA (1) CA2303934C (pt)
CO (1) CO5070656A1 (pt)
CZ (1) CZ299365B6 (pt)
DE (1) DE69830502T2 (pt)
DK (1) DK1015459T3 (pt)
ES (1) ES2244087T3 (pt)
HK (1) HK1030771A1 (pt)
HU (1) HU228368B1 (pt)
IL (2) IL134607A0 (pt)
NO (1) NO325813B1 (pt)
NZ (2) NZ502896A (pt)
PL (1) PL191212B1 (pt)
PT (1) PT1015459E (pt)
SI (1) SI1015459T1 (pt)
SK (1) SK285408B6 (pt)
TR (1) TR200000778T2 (pt)
TW (1) TW557297B (pt)
WO (1) WO1999015530A1 (pt)
ZA (1) ZA988750B (pt)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US7399480B2 (en) 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US7357942B2 (en) * 1997-09-26 2008-04-15 Abbott Laboratories Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens
US7960405B2 (en) 1998-09-24 2011-06-14 Abbott Laboratories Compounds and methods for treatment and prevention of diseases
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20050163781A1 (en) * 2002-01-29 2005-07-28 Philippe Koninckx Tissue adhesion formation control
US20030176455A1 (en) * 2002-03-13 2003-09-18 Wyeth Method of inhibiting cell death
NZ560662A (en) 2002-05-16 2009-09-25 Novartis Ag Use of EDG receptor binding agents in cancer
CA2486853A1 (en) 2002-05-27 2003-12-04 Novartis Ag Bis-aromatic alkanols
NZ538568A (en) * 2002-09-06 2010-09-30 Abbott Lab Medical device having hydration inhibitor
CN1708293A (zh) 2002-09-24 2005-12-14 诺瓦提斯公司 治疗脱髓鞘疾病的鞘氨醇－1－磷酸受体激动剂
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
TW200505442A (en) 2003-05-19 2005-02-16 Genomics Inst Of The Novartis Res Foundation Immunosuppressant compounds and compositions
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
CA2585840A1 (en) 2004-10-28 2006-05-11 Wyeth Use of an mtor inhibitor in treatment of uterine leiomyoma
GB0504544D0 (en) 2005-03-04 2005-04-13 Novartis Ag Organic compounds
US8298565B2 (en) 2005-07-15 2012-10-30 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
US20090062909A1 (en) 2005-07-15 2009-03-05 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
PT2298815E (pt) 2005-07-25 2015-07-16 Emergent Product Dev Seattle Moléculas de ligaçao especificas para cd37 e especificas para cd20
WO2007027751A2 (en) 2005-08-30 2007-03-08 University Of Miami Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists and immunotoxins
CN103110948A (zh) 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
US7700614B2 (en) * 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
ES2540059T3 (es) 2006-04-26 2015-07-08 Micell Technologies, Inc. Recubrimientos que contienen múltiples fármacos
WO2008014222A1 (en) 2006-07-25 2008-01-31 Abbott Laboratories Crystalline forms of rapamycin analogs
US7812032B2 (en) 2006-07-25 2010-10-12 Abbott Laboratories Crystalline forms of rapamycin analogs
US7820812B2 (en) 2006-07-25 2010-10-26 Abbott Laboratories Methods of manufacturing crystalline forms of rapamycin analogs
JP5603598B2 (ja) 2007-01-08 2014-10-08 ミセル テクノロジーズ、インコーポレイテッド 生物分解層を有するステント
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
TW200901989A (en) 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
EP2278966B1 (en) 2008-03-21 2019-10-09 The University of Chicago Treatment with opioid antagonists and mtor inhibitors
WO2009126944A1 (en) 2008-04-11 2009-10-15 Trubion Pharmaceuticals, Inc. Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
EP3360586B1 (en) 2008-04-17 2024-03-06 Micell Technologies, Inc. Stents having bioabsorbable layers
CA2728514C (en) 2008-06-20 2020-08-11 Novartis Ag Paediatric compositions for treating multiple sclerosis
WO2011009096A1 (en) 2009-07-16 2011-01-20 Micell Technologies, Inc. Drug delivery medical device
CA2946195A1 (en) 2008-07-17 2010-01-21 Micell Technologies, Inc. Drug delivery medical device
AU2009327405A1 (en) 2008-12-18 2011-06-30 Novartis Ag New polymorphic form of 1- (4- { l- [ (E) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino] -ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic
SG171785A1 (en) 2008-12-18 2011-07-28 Novartis Ag Hemifumarate salt of 1- [4- [1- ( 4 -cyclohexyl-3 -trifluoromethyl-benzyloxyimino ) -ethyl] -2 -ethyl-benzyl] -a zetidine-3-carboxylic acid
BRPI0922466A2 (pt) 2008-12-18 2018-10-23 Novartis Ag sais
CN102481195B (zh) 2009-04-01 2015-03-25 米歇尔技术公司 涂覆支架
WO2010121187A2 (en) 2009-04-17 2010-10-21 Micell Techologies, Inc. Stents having controlled elution
AU2010279637B2 (en) 2009-08-03 2012-08-23 University Of Miami Method for in vivo expansion of T regulatory cells
AU2010313152A1 (en) 2009-10-30 2012-04-19 Ariad Pharmaceuticals, Inc. Methods and compositions for treating cancer
US11369498B2 (en) 2010-02-02 2022-06-28 MT Acquisition Holdings LLC Stent and stent delivery system with improved deliverability
EA020528B1 (ru) 2010-02-11 2014-11-28 Бристол-Майерс Сквибб Компани Макроциклы в качестве ингибиторов фактора xia
WO2011133655A1 (en) 2010-04-22 2011-10-27 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
CA2795544A1 (en) 2010-04-27 2011-11-03 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor
CN102234288B (zh) * 2010-05-06 2014-07-02 上海医药工业研究院 唑他莫司的制备方法
EP2593039B1 (en) 2010-07-16 2022-11-30 Micell Technologies, Inc. Drug delivery medical device
PT2675451E (pt) 2011-02-18 2015-10-16 Incyte Corp Terapia de combinação com inibidores mtor/jak
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013012689A1 (en) 2011-07-15 2013-01-24 Micell Technologies, Inc. Drug delivery medical device
PE20141825A1 (es) 2011-10-14 2014-11-29 Bristol Myers Squibb Co Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor xia
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
US9403774B2 (en) 2012-10-12 2016-08-02 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
WO2014059202A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
EA032092B1 (ru) 2012-10-12 2019-04-30 Бристол-Майерс Сквибб Компани Кристаллические формы ингибитора фактора xia
AU2012395673A1 (en) * 2012-11-30 2014-08-14 Hangzhou Zylox Pharma Co., Ltd. Rapamycin analogs and methods for making same
KR20210041631A (ko) 2013-01-09 2021-04-15 유니버시티 오브 마이애미 TL1A-Ig 융합 단백질을 사용한 T 조절 세포의 조절을 위한 조성물 및 방법
EP2967803B1 (en) 2013-03-12 2023-12-27 Micell Technologies, Inc. Bioabsorbable biomedical implants
WO2014160668A1 (en) 2013-03-25 2014-10-02 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors
US10272606B2 (en) 2013-05-15 2019-04-30 Micell Technologies, Inc. Bioabsorbable biomedical implants
KR20160084438A (ko) 2013-11-13 2016-07-13 노파르티스 아게 면역 반응을 강화하기 위한 mTOR 억제제
CA3225453A1 (en) 2013-12-19 2015-06-25 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
EP3087101B1 (en) 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
CN103739616B (zh) * 2013-12-27 2015-12-30 福建省微生物研究所 含噻唑基雷帕霉素类衍生物及其应用
EP3094314B1 (en) 2014-01-16 2021-06-23 MUSC Foundation For Research Development Targeted nanocarriers for the administration of immunosuppressive agents
EP3988549A1 (en) 2014-01-31 2022-04-27 Bristol-Myers Squibb Company Macrocycles with heterocyclic p2' groups as factor xia inhibitors
NO2760821T3 (pt) 2014-01-31 2018-03-10
EP3811970A1 (en) 2014-03-15 2021-04-28 Novartis AG Regulatable chimeric antigen receptor
JP2017513818A (ja) 2014-03-15 2017-06-01 ノバルティス アーゲー キメラ抗原受容体を使用する癌の処置
EP3122376A4 (en) 2014-03-27 2017-12-20 The Brigham and Women's Hospital, Inc. Metabolically-activated drug conjugates to overcome resistance in cancer therapy
HUE054588T2 (hu) 2014-04-07 2021-09-28 Novartis Ag Rák kezelése CD19 elleni, kiméra antigénreceptor alkalmazásával
WO2015187541A1 (en) 2014-06-02 2015-12-10 Children's Medical Center Corporation Methods and compositions for immunomodulation
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
CA2955154C (en) 2014-07-21 2023-10-31 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
EP3193915A1 (en) 2014-07-21 2017-07-26 Novartis AG Combinations of low, immune enhancing. doses of mtor inhibitors and cars
EP4205749A1 (en) 2014-07-31 2023-07-05 Novartis AG Subset-optimized chimeric antigen receptor-containing cells
CA2958200A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
PL3183268T3 (pl) 2014-08-19 2020-09-07 Novartis Ag Chimeryczny receptor antygenowy (CAR) anty-CD123 do zastosowania w leczeniu nowotworu złośliwego
WO2016036893A1 (en) 2014-09-04 2016-03-10 Bristol-Myers Squibb Company Diamide macrocycles that are fxia inhibitors
WO2016044605A1 (en) 2014-09-17 2016-03-24 Beatty, Gregory Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
KR20170068504A (ko) 2014-10-08 2017-06-19 노파르티스 아게 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
CA2982996A1 (en) 2015-04-17 2016-10-20 David Maxwell Barrett Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
JP6857141B2 (ja) 2015-05-20 2021-04-14 ノバルティス アーゲー エベロリムスとダクトリシブとの薬学的組合せ
WO2017081624A1 (en) 2015-11-11 2017-05-18 Novartis Ag Uses of myostatin antagonists, combinations containing them and uses thereof
US11365252B2 (en) 2016-07-20 2022-06-21 University Of Utah Research Foundation CD229 CAR T cells and methods of use thereof
CN117866991A (zh) 2016-10-07 2024-04-12 诺华股份有限公司 用于治疗癌症的嵌合抗原受体
CA3044355A1 (en) 2016-11-23 2018-05-31 Novartis Ag Methods of enhancing immune response with everolimus, dactolisib or both
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
US20210047405A1 (en) 2018-04-27 2021-02-18 Novartis Ag Car t cell therapies with enhanced efficacy
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
CA3107349A1 (en) 2018-07-23 2020-01-30 Enclear Therapies, Inc. Methods of treating neurological disorders
AU2019310040A1 (en) 2018-07-23 2021-02-11 Enclear Therapies, Inc. Methods of treating neurological disorders
JP2022526671A (ja) 2019-04-11 2022-05-25 エンクリアー セラピーズ， インク． 脳脊髄液の改善の方法ならびにそのためのデバイスおよびシステム
WO2022098642A1 (en) 2020-11-03 2022-05-12 Rdiscovery, LLC Therapies for treatment of cancer and phagocytosis-deficiency related diseases
CA3223081A1 (en) 2021-07-15 2023-01-19 Samir Mitragotri Compositions and methods relating to cells with adhered particles
CN116082362B (zh) * 2023-01-04 2024-05-10 山东大学 一种可用于合成靶向抗肿瘤药物的氨甲酰美登醇及其合成方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2175215C (en) * 1993-11-19 2008-06-03 Yat Sun Or Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
WO1998009972A1 (en) * 1996-09-09 1998-03-12 American Home Products Corporation Rapamycin derivatives with unnatural stereochemistries
JP2001500126A (ja) * 1996-09-09 2001-01-09 アメリカン・ホーム・プロダクツ・コーポレイション アルキル化ラパマイシン誘導体

Also Published As

Publication number Publication date
ATE297398T1 (de) 2005-06-15
NZ502896A (en) 2001-12-21
JP3790424B2 (ja) 2006-06-28
ZA988750B (en) 1999-04-01
AU9581998A (en) 1999-04-12
SI1015459T1 (en) 2005-10-31
AR015940A1 (es) 2001-05-30
EP1015459B9 (en) 2005-10-12
AU745576B2 (en) 2002-03-21
NO20001438D0 (no) 2000-03-20
PL339455A1 (en) 2000-12-18
EP1015459A1 (en) 2000-07-05
CA2303934C (en) 2010-01-26
CN1161360C (zh) 2004-08-11
IL134607A (en) 2006-04-10
HK1030771A1 (en) 2001-05-18
TW557297B (en) 2003-10-11
IL134607A0 (en) 2001-04-30
ES2244087T3 (es) 2005-12-01
DE69830502D1 (de) 2005-07-14
TR200000778T2 (tr) 2000-07-21
HUP0004556A3 (en) 2001-12-28
HU228368B1 (en) 2013-03-28
CZ299365B6 (cs) 2008-07-02
KR20060071092A (ko) 2006-06-26
BG64955B1 (bg) 2006-10-31
CN1271361A (zh) 2000-10-25
KR20010024298A (ko) 2001-03-26
BG104316A (en) 2000-12-29
DE69830502T2 (de) 2006-05-11
CA2303934A1 (en) 1999-04-01
NO20001438L (no) 2000-05-26
CO5070656A1 (es) 2001-08-28
SK285408B6 (sk) 2007-01-04
NZ514778A (en) 2005-01-28
KR100833812B1 (ko) 2008-05-30
KR100803639B1 (ko) 2008-02-19
NO325813B1 (no) 2008-07-21
KR20070086925A (ko) 2007-08-27
CZ20001014A3 (cs) 2000-07-12
DK1015459T3 (da) 2005-10-10
KR100700319B1 (ko) 2007-03-29
WO1999015530A1 (en) 1999-04-01
SK4172000A3 (en) 2000-08-14
PL191212B1 (pl) 2006-03-31
EP1015459B1 (en) 2005-06-08
HUP0004556A2 (hu) 2001-10-28
PT1015459E (pt) 2005-09-30
JP2001517671A (ja) 2001-10-09

Similar Documents

Publication Publication Date Title
BR9812305A (pt) Análogos de rapamicina contendo tetrazol com meias vidas encurtadas
DE69720773D1 (de) SAUERSTOFF ODER SCHWEFEL ENTHALTENDE 5-GLIEDRIGE HETEROAROMATISHE DERIVATIVE ALS FACTOR Xa HEMMER
TW200626592A (en) Heterocyclic derivatives and their use as therapeutic agents
ES2147836T3 (es) Derivados de 4,5-diariloxazol.
HK1021699A1 (en) Pentafluorobenzenesulfonamides and analogs.
TW200626154A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200626138A (en) Heterocyclic derivatives and their use as therapeutic agents
TW200626155A (en) Heterocyclic derivatives and their use as therapeutic agents
DE69622031D1 (de) INDOLDERIVATE ALS cGMP-PDE INHIBITOREN
WO1996016981A3 (en) Peptide compounds for prevention and/or treatment of no-mediated diseases
TW200518753A (en) Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
ATE269310T1 (de) Pyridopyrimidinone, chinoline und anellierte n- heterozyklen als bradykinin-antagonisten
NZ325449A (en) Naphthyl-substituted benzimidazole derivatives as anticoagulants
HUP0001358A2 (hu) QT diszperzió és szívverés változékonyság javítása CRF antagonista hatású heterociklusos vegyületek alkalmazásával hirtelen halál megelőzése céljából
ES2160156T3 (es) Derivados de naftaleno como agonistas de la prostaglandina i2.
EP0896533A4 (en) PENTAFLUOROBENZEN SULPHONAMIDES AND ANALOGS
ES2132393T3 (es) Derivados de guanidina utiles en terapeutica.
DE69717148D1 (de) 3-pyridylenantiomere und ihre verwendung als analgetika
PT986393E (pt) Utilizacao de um nitroxido ou de um seu pro-farmaco no tratamento profilactico e terapeutico do cancro
TR200103561T2 (tr) Rodanin türevleri ve amiloidlerin önlenmesi ve görüntülenmesinde kullanımları
FR2618435B1 (fr) Derives de benzimidazole, leur preparation et leur application en therapeutique
CY2525B1 (en) Use of penciclovir for the treatment of human herpes-virus-8
TR200100088T2 (tr) Tedavi metodu
DK0626383T3 (da) Palau'amin: Farmakologisk aktiv forbindelse fra en svamp
AU637502B2 (en) Agents for treating addiction to habit-forming drugs

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: C07D 498/18, A61K 31/436, A61P 31/10, A61P 37/02, A61P 37/06

Ipc: C07D 498/18 (2007.10), A61K 31/436 (2007.10), A61P

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO COM BASE NOS ARTIGOS 8O, 10 ( VIII ), 13, 24 E 25 DA LEI 9.279 DE 14 DE MAIO DE 1996 ( LPI )

B12B Appeal against refusal [chapter 12.2 patent gazette]
B15W Others matters related to applications: legal action concerning application

Free format text: INPI NO 52400.029129/2016-66 ORIGEM: 025O VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 00050369220164025101 ACAO ORDINARIA DE NULIDADE DE ATO ADMINISTRATIVO AUTOR: ABBOTT LABORATORIES REU: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI.

B15N Others concerning applications: notification of judicial decision
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B15N Others concerning applications: notification of judicial decision

Free format text: INPI-52402.029129/2016-66 SECAO JUDICIARIA DO RIO DO JANEIRO 25A VARA FEDERAL DO RIO DE JANEIRO PROCESSO: NO0005036-92.2016.4.02.5101 AUTOR: ABBOTT LABORATORIESREU: INPI-INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL DECISAO: TRANSITOU EM JULGADO EM 17/12/2019. CONFORME ACORDAO QUE REFORMOU A SENTENCA E MANTEVE O ATO DE INDEFERIMENTO DESTE PEDIDO DE PATENTE PI 9812305-0.

B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time